Breaking Finance News

A statement released earlier today by Stifel about Clinigen Group (LON:CLIN) maintains the target price at 800.00GBX

Boasting a price of 709.75GBX, Clinigen Group (LON:CLIN) traded -1.31% lower on the day. With the last stock price close up 13.51% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Clinigen Group has recorded a 50-day average of 651.96GBX and a two hundred day average of 596.84GBX. Volume of trade was down over the average, with 228,982 shares of CLIN changing hands under the typical 496,983

Stifel hold steady the target price of Clinigen Group (LON:CLIN) at 800.00GBX indicating a possible upside of 0.13%.

On 7/20/2016, numis released a statement for Clinigen Group (LON:CLIN) bumped up the target price from 0.00GBX to 916.00GBX that suggested an upside of 0.34%.

Performance Chart

Clinigen Group (LON:CLIN)

With a total market value of 0 GBX, Clinigen Group has with a one year low of 492.75GBX and a one year high of 723.50GBX .

A total of 5 equity analysts have released a ratings update on the stock. 3 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 850.00GBX.

More About Clinigen Group (LON:CLIN)

Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). The CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. The MA segment specializes in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies. The GA segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these often-essential drugs. The SP segment manufactures and distributes its own and in-license specialist, hospital-only medicines.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *